Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: Business Wire
Clinical Results and Potential New Drug Application Submission Expected in the Second Half of 2024 LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced enrollment of the first patient in a Phase 3 dry eye chamber clinical trial designed to enable a potential resubmission of the New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease.Contingent on positive results from the clinical trial, Aldeyra expects to resubmit the NDA of reproxalap for the treatment of dry eye disease to the U.S. Food and Drug Administration (FDA) in the second half of 2024. Aldeyra intends to include in the potential NDA resubmission a draft label describing chronic and acute improvement in symptoms and ocular redness. To Aldeyra’s knowledge,
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
ALDX
Earnings
- 5/2/24 - Miss
ALDX
Sec Filings
- 5/2/24 - Form 10-Q
- 4/25/24 - Form 8-K
- 4/25/24 - Form EFFECT
- ALDX's page on the SEC website